Revive Therapeutics Ltd (RVVTF)

[ReikoBlack]

Why would a reverse split be necessary to procure funding? In February 2021, Revive raised $23,000,000 in an Offering. ("46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000")

("Each Unit is comprised of one common share of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.70 per Common Share until February 12, 2024. If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “Exchange”) is greater than $1.10 for the preceding ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date on which the Company issues a press release announcing the reduced warrant term.")

If we see favorable results with Bucillamine then Revive's share price will reflect the favorable results. Revive could then procure additional funding through the warrants or do a similar Offering at a higher share price. Dilutive, yes...but a reverse split is not necessary.

Nos....I really hope not,made me feel a little woozy thinking about it....also seen this on a couple other forums where they were saying a R/S might be needed for funding. Again this stuff is way about my head and not sure how it all works.